Post-BCG Maintenance Cystoscopy: Interpreting a Subtle Lesion
A 68-year-old man with a 40-pack-year smoking history was diagnosed 14 months ago with a 2.5 cm high-grade Ta urothelial carcinoma of the right lateral wall. He underwent complete TURBT with muscularis propria in the specimen, followed by induction intravesical BCG (6 instillations) and two maintenance cycles. Surveillance cystoscopy today shows a 4 mm slightly raised erythematous area at the prior resection site. Urine cytology is atypical, not diagnostic. He is asymptomatic and has no gross hematuria. Renal function is normal (eGFR 72). He asks whether he can simply continue maintenance BCG and recheck in 3 months because he 'feels fine' and the spot is tiny.
1. How should the 4 mm erythematous lesion be managed at this visit, and why is watchful waiting with continued BCG inappropriate?
Read the worked answer
A new focal lesion in a patient with prior high-grade disease must be considered recurrence until proven otherwise, regardless of size or symptoms. The correct step is office cystoscopy with directed cold-cup biopsy (and/or repeat TURBT if the lesion is resectable and muscle-invasive concern exists) plus upper tract evaluation as indicated. Key reasoning:
- High-grade history changes the prior probability. Any visible lesion after BCG in a high-grade patient carries a meaningful risk of persistent high-grade/CIS or progression; size does not predict grade.
- BCG can induce granulomatous inflammation that mimics tumor, so biopsy distinguishes treatment effect from recurrence - you cannot tell by appearance alone.
- Continuing BCG without tissue diagnosis risks delaying diagnosis of progression and also may be futile if the disease is BCG-unresponsive.
- Cytology 'atypical' is non-diagnostic and does not lower the need for biopsy.
If biopsy confirms high-grade recurrence at this point (after adequate BCG), the patient meets criteria for BCG-unresponsive disease, and the discussion shifts to cystectomy versus clinical trial/alternative intravesical therapy rather than further BCG.
2. The biopsy returns high-grade Ta with CIS at the resection site. He has received adequate BCG (induction plus at least two maintenance cycles). What are the management options and the recommended framing of the conversation?
Read the worked answer
This is BCG-unresponsive non-muscle-invasive bladder cancer (high-grade recurrence within 6 months of adequate BCG, or CIS within 12 months). Management:
- Radical cystectomy with urinary diversion - the guideline-concordant standard with the most durable oncologic control. He should be counseled that delaying cystectomy in BCG-unresponsive disease is associated with worse outcomes, particularly with CIS.
- Clinical trial enrollment - preferred alternative if he declines or is unfit for cystectomy.
- Alternative intravesical agents (e.g., nadofaragene, pembrolizumab intravesical/systemic, valrubicin, gemcitabine/docetaxel) - reasonable in patients who are not cystectomy candidates, with the explicit understanding that these are bladder-sparing and carry progression risk requiring strict surveillance.
Conversation framing: present cystectomy as the oncologically strongest option, quantify that BCG-unresponsive CIS carries substantial progression risk, and clarify that repeat BCG is not recommended. Document shared decision-making. If he elects bladder preservation, set explicit surveillance intervals (cytology plus cystoscopy every 3 months) and predefine the trigger for cystectomy.